Renal function assessment during peptide receptor radionuclide therapy

B Erbas, M Tuncel - Seminars in Nuclear Medicine, 2016 - Elsevier
Theranostics labeled with Y-90 or Lu-177 are highly efficient therapeutic approaches for the
systemic treatment of various cancers including neuroendocrine tumors and prostate cancer …
被引用次数：42 相关文章

Renal Function Assessment During Peptide Receptor Radionuclide Therapy.

B Erbas, M Tuncel - Seminars in Nuclear Medicine, 2016 - europepmc.org
Theranostics labeled with Y-90 or Lu-177 are highly efficient therapeutic approaches for the
systemic treatment of various cancers including neuroendocrine tumors and prostate cancer …

Renal Function Assessment During Peptide Receptor Radionuclide Therapy

H Erbas, M TUNCEL - SEMINARS IN NUCLEAR …, 2016 - avesis.hacettepe.edu.tr
Theranostics labeled with Y-90 or Lu-177 are highly efficient therapeutic approaches for the
systemic treatment of various cancers including neuroendocrine tumors and prostate cancer …

Renal Function Assessment During Peptide Receptor Radionuclide Therapy

B Erbas, M Tuncel - Seminars in Nuclear Medicine, 2016 - hero.epa.gov
Theranostics labeled with Y-90 or Lu-177 are highly efficient therapeutic approaches for the
systemic treatment of various cancers including neuroendocrine tumors and prostate cancer …

Renal Function Assessment During Peptide Receptor Radionuclide Therapy

B Erbas, M Tuncel - Seminars in nuclear medicine, 2016 - pubmed.ncbi.nlm.nih.gov
Theranostics labeled with Y-90 or Lu-177 are highly efficient therapeutic approaches for the
systemic treatment of various cancers including neuroendocrine tumors and prostate cancer …

Renal Function Assessment During Peptide Receptor Radionuclide Therapy

B Erbas, M Tuncel - Seminars in Nuclear Medicine, 2016 - infona.pl
Theranostics labeled with Y-90 or Lu-177 are highly efficient therapeutic approaches for the
systemic treatment of various cancers including neuroendocrine tumors and prostate cancer …